Capital Investment Advisors LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 387,492 shares of the biopharmaceutical company’s stock after purchasing an additional 9,791 shares during the period. Capital Investment Advisors LLC’s holdings in Gilead Sciences were worth $35,793,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Parallel Advisors LLC increased its position in shares of Gilead Sciences by 27.0% in the second quarter. Parallel Advisors LLC now owns 58,123 shares of the biopharmaceutical company’s stock valued at $3,988,000 after buying an additional 12,349 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Gilead Sciences by 20.5% during the second quarter. Oppenheimer Asset Management Inc. now owns 183,224 shares of the biopharmaceutical company’s stock worth $12,571,000 after acquiring an additional 31,148 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its holdings in shares of Gilead Sciences by 7.5% in the second quarter. Retirement Planning Co of New England Inc. now owns 12,342 shares of the biopharmaceutical company’s stock valued at $847,000 after purchasing an additional 858 shares in the last quarter. WINTON GROUP Ltd increased its stake in shares of Gilead Sciences by 52.9% during the 2nd quarter. WINTON GROUP Ltd now owns 8,800 shares of the biopharmaceutical company’s stock worth $604,000 after purchasing an additional 3,043 shares in the last quarter. Finally, Providence Wealth Advisors LLC raised its position in shares of Gilead Sciences by 5.3% during the 2nd quarter. Providence Wealth Advisors LLC now owns 14,097 shares of the biopharmaceutical company’s stock worth $981,000 after purchasing an additional 709 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 453,734 shares of company stock valued at $41,902,086. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wolfe Research initiated coverage on Gilead Sciences in a report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price on the stock. Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. The Goldman Sachs Group raised their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $97.96.

Gilead Sciences Stock Up 0.0 %

NASDAQ GILD traded up $0.03 during trading hours on Monday, hitting $89.91. The company had a trading volume of 1,668,647 shares, compared to its average volume of 5,385,106. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The firm’s 50 day moving average is $91.94 and its 200 day moving average is $83.39. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market capitalization of $112.05 billion, a price-to-earnings ratio of 999.00, a P/E/G ratio of 2.24 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the company posted $2.29 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were paid a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.43%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.